Maxygen, Inc.
411 Borel Avenue
Suite 616
San Mateo,
CA 94402
United States - Map
Phone: 650-241-2292
Fax: 650-257-5892
Website: http://www.maxygen.com
Maxygen, Inc., a biopharmaceutical company, focuses on the discovery and development of protein pharmaceuticals for the treatment of disease and serious medical conditions in the United States. It focuses on developing MAXY-G34 product candidate, a granulocyte colony stimulating factor, for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome. The company was founded in 1996 and is headquartered in San Mateo, California. Key Statistics
| |
| Maxygen, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 7. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 2; Compensation: 8. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. Isaac Associates Stein J.D., M.B.A.,
66
Exec. Chairman of The Board and Member of Alliances Committee | 650.00K | N/A | Mr. James R. Sulat MBA,
63
Chief Exec. Officer, Chief Financial Officer, Principal Accounting Officer, Director and Member of Alliances Committee | 774.00K | 0.00 | Mr. John M. Borkholder J.D.,
44
Gen. Counsel and Corp. Sec. | 343.00K | 0.00 | Dr. Norman Kruse ,
Chief Patent Counsel and VP of Intellectual Property | N/A | N/A | Dr. R. Paul Spence M.D., D.phil,
56
Sr. VP of R&D | N/A | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.02(0.85%) May 17, 4:00PM EDT